MetLife Investment Management’s CONMED CNMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$632K Buy
19,310
+871
+5% +$31.4K ﹤0.01% 1778
2026
Q1
$652K Sell
18,439
-136
-0.7% -$5.53K ﹤0.01% 1624
2025
Q4
$754K Hold
18,575
﹤0.01% 1588
2025
Q3
$874K Hold
18,575
﹤0.01% 1530
2025
Q2
$967K Sell
18,575
-32
-0.2% -$1.76K 0.01% 1333
2025
Q1
$1.12M Sell
18,607
-279
-1% -$18K 0.01% 1306
2024
Q4
$1.29M Buy
18,886
+1,250
+7% +$87.1K 0.01% 1290
2024
Q3
$1.27M Hold
17,636
0.01% 1258
2024
Q2
$1.22M Buy
17,636
+1,887
+12% +$138K 0.01% 1241
2024
Q1
$1.26M Sell
15,749
-414
-3% -$36.9K 0.01% 1169
2023
Q4
$1.77M Hold
16,163
0.01% 994
2023
Q3
$1.63M Hold
16,163
0.01% 999
2023
Q2
$2.2M Buy
16,163
+836
+5% +$102K 0.02% 897
2023
Q1
$1.59M Hold
15,327
0.01% 996
2022
Q4
$1.36M Hold
15,327
0.01% 1063
2022
Q3
$1.23M Buy
15,327
+307
+2% +$29K 0.01% 1087
2022
Q2
$1.44M Sell
15,020
-369
-2% -$44.3K 0.01% 1037
2022
Q1
$2.29M Buy
15,389
+5,522
+56% +$771K 0.01% 939
2021
Q4
$1.4M Sell
9,867
-590
-6% -$83.6K 0.01% 989
2021
Q3
$1.37M Hold
10,457
0.01% 985
2021
Q2
$1.44M Hold
10,457
0.01% 998
2021
Q1
$1.37M Sell
10,457
-933
-8% -$112K 0.01% 994
2020
Q4
$1.28M Hold
11,390
0.01% 1023
2020
Q3
$896K Sell
11,390
-1,063
-9% -$86.7K 0.01% 1079
2020
Q2
$896K Buy
12,453
+1,053
+9% +$73.3K 0.01% 1080
2020
Q1
$653K Hold
11,400
0.01% 1073
2019
Q4
$1.27M Sell
11,400
-887
-7% -$94.5K 0.01% 975
2019
Q3
$1.18M Hold
12,287
0.01% 990
2019
Q2
$1.05M Buy
12,287
+604
+5% +$49.7K 0.01% 1078
2019
Q1
$972K Hold
11,683
0.01% 1098
2018
Q4
$750K Hold
11,683
0.01% 1137
2018
Q3
$926K Hold
11,683
0.01% 1168
2018
Q2
$855K Sell
11,683
-1,688
-13% -$115K 0.01% 1094
2018
Q1
$847K Hold
13,371
0.01% 1078
2017
Q4
$682K Buy
+13,371
New +$696K 0.01% 1219

Other funds holding CNMD

MetLife Investment Management's CNMD Position: Q2 2026 in Review

MetLife Investment Management increased its CONMED (CNMD) stake by 4.7% in Q2 2026, buying an estimated $31.4K and bringing the position to 19,310 shares worth $632K. The position accounts for ﹤0.01% of the portfolio, ranked #1778.

MetLife Investment Management first reported a position in CNMD in Q4 2017 and has held it in 35 quarters since. The position peaked at $2.29M in Q1 2022. 246 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

  • MetLife Investment Management held 19,310 shares of CONMED worth $632K as of Q2 2026.
  • MetLife Investment Management bought 871 CONMED shares in Q2 2026, an estimated $31.4K.
  • CONMED made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1778 holding.
  • MetLife Investment Management first reported a position in CONMED in Q4 2017 and has held it in 35 quarters since.
  • MetLife Investment Management's CONMED position peaked at $2.29M in Q1 2022.
  • 246 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.